The impact of glutamate infusion on postoperative NT-proBNP in patients undergoing coronary artery bypass surgery: a randomized study

Huiqi Jiang, Jonas Holm, Mårten Vidlund, Farkas Vanky, Örjan Friberg, Yanqi Yang, Rolf Svedjeholm, Huiqi Jiang, Jonas Holm, Mårten Vidlund, Farkas Vanky, Örjan Friberg, Yanqi Yang, Rolf Svedjeholm

Abstract

Background: Glutamate, a key intermediate in myocardial metabolism, may enhance myocardial recovery after ischemia and possibly reduce the incidence and severity of postoperative heart failure in coronary artery bypass surgery (CABG). N-terminal pro-B-type natriuretic peptide (NT-proBNP) can be used to assess postoperative heart failure (PHF) after CABG. Our hypothesis was that glutamate enhances myocardial recovery in post-ischemic heart failure and, therefore, will be accompanied by a mitigated postoperative increase of NT-proBNP.

Methods: Substudy of the GLUTAmate for Metabolic Intervention in Coronary Surgery (GLUTAMICS) trial (ClinicalTrials.gov Identifier: NCT00489827) a prospective triple-center double-blind randomized clinical trial on 399 patients undergoing CABG with or without concomitant procedure for acute coronary syndrome at three Swedish Cardiac Surgery centres (Linköping, Örebro, and Karlskrona) from May 30, 2007 to November 12, 2009. Patients were randomly assigned to intravenous infusion of 0.125 M L-glutamic acid or saline (1.65 mL/kg of body weight per hour) intraoperatively and postoperatively. Plasma NT-proBNP was measured preoperatively, the first (POD1) and third postoperative morning (POD3). A Clinical Endpoints Committee, blinded to both intervention and NT-proBNP used prespecified criteria to diagnose PHF. The primary endpoints were the absolute levels of postoperative NT-proBNP and the difference between preoperative and postoperative levels of NT-proBNP.

Results: Overall no significant difference was detected in postoperative NT-proBNP levels between groups. However, in high-risk patients (upper quartile of EuroSCORE II ≥ 4.15; glutamate group n = 56; control group n = 45) glutamate was associated with significantly lower postoperative increase of NT-proBNP (POD3-Pre: 3900 [2995-6260] vs. 6745 [3455-12,687] ng•L-1, p = 0.012) and lower NT-proBNP POD3 (POD3: 4845 [3426-7423] vs. 8430 [5370-14,100] ng•L-1, p = 0.001). After adjusting for significant differences in preoperative demographics, NT-proBNP POD3 in the glutamate group was 0.62 times of that in the control group (p = 0.002). Patients in the glutamate group also had shorter ICU stay (21 [19-26] vs. 25 [22-46] h, p = 0.025) and less signs of myocardial injury (Troponin T POD3 (300 [170-500] vs. 560 [210-910] ng•L-1, p = 0.025).

Conclusions: Post hoc analysis of postoperative NT-proBNP suggests that intravenous infusion of glutamate may prevent or mitigate myocardial dysfunction in high-risk patients undergoing CABG. Further studies are necessary to confirm these findings. Trial registration Swedish Medical Products Agency 151:2003/70403 (prospectively registered with amendment about this substudy filed March 17, 2007). ClinicalTrials.gov Identifier: NCT00489827 (retrospectively registered) https://ichgcp.net/clinical-trials-registry/NCT00489827?term=glutamics&draw=1&rank=1.

Keywords: Coronary artery bypass surgery; Glutamic acid; Heart failure; Natriuretic peptide; Postoperative care.

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Flow chart of the patients
Fig. 2
Fig. 2
Perioperative NT-proBNP levels in patients with EuroSCORE II ≥ 4.15 (upper quartile). Data expressed as medians with interquartile range. *p POD postoperative day, Preop preoperative

References

    1. O’Connor GT, Birkmeyer JD, Dacey LJ, Quinton HB, Marrin CA, Birkmeyer NJ, Morton JR, Leavitt BJ, Maloney CT, Hernandez F, Clough RA, Nugent WC, Olmstead EM, Charlesworth DC, Plume SK. Results of a regional study of modes of death associated with coronary artery bypass grafting. Northern New England Cardiovascular Disease Study Group. Ann Thorac Surg. 1998;66:1323–1328. doi: 10.1016/S0003-4975(98)00762-0.
    1. Surgenor SD, O’Connor GT, Lahey SJ, Quinn R, Charlesworth DC, Dacey LJ, Clough RA, Leavitt BJ, Defoe GR, Fillinger M, Nugent WC, Northern New England Cardiovascular Disease Study G Predicting the risk of death from heart failure after coronary artery bypass graft surgery. Anesth Analg. 2001;92:596–601. doi: 10.1213/00000539-200103000-00008.
    1. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P, Authors/Task Force M, Document R 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18:891–975. doi: 10.1002/ejhf.592.
    1. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Jr, Colvin MM, Drazner MH, Filippatos GS, Fonarow GC, Givertz MM, Hollenberg SM, Lindenfeld J, Masoudi FA, McBride PE, Peterson PN, Stevenson LW, Westlake C. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the Heart Failure Society of America. J Card Fail. 2017;23:628–651. doi: 10.1016/j.cardfail.2017.04.014.
    1. Reyes G, Fores G, Rodriguez-Abella RH, Cuerpo G, Vallejo JL, Romero C, Pinto A. NT-proBNP in cardiac surgery: a new tool for the management of our patients? Interact Cardiovasc Thorac Surg. 2005;4:242–247. doi: 10.1510/icvts.2004.101576.
    1. Fox AA, Shernan SK, Collard CD, Liu KY, Aranki SF, DeSantis SM, Jarolim P, Body SC. Preoperative B-type natriuretic peptide is as independent predictor of ventricular dysfunction and mortality after primary coronary artery bypass grafting. J Thorac Cardiovasc Surg. 2008;136:452–461. doi: 10.1016/j.jtcvs.2007.12.036.
    1. Nozohoor S, Nilsson J, Luhrs C, Roijer A, Algotsson L, Sjogren J. B-type natriuretic peptide as a predictor of postoperative heart failure after aortic valve replacement. J Cardiothorac Vasc Anesth. 2009;23:161–165. doi: 10.1053/j.jvca.2008.11.006.
    1. Suttner S, Boldt J, Lang K, Rohm KD, Piper SN, Mayer J. Association of N-terminal pro-brain natriuretic peptide and cardiac troponin T with in-hospital cardiac events in elderly patients undergoing coronary artery surgery. Eur J Anaesthesiol. 2008;25:834–841. doi: 10.1017/S0265021508004365.
    1. Provenchere S, Berroeta C, Reynaud C, Baron G, Poirier I, Desmonts JM, Iung B, Dehoux M, Philip I, Benessiano J. Plasma brain natriuretic peptide and cardiac troponin I concentrations after adult cardiac surgery: association with postoperative cardiac dysfunction and 1-year mortality. Crit Care Med. 2006;34:995–1000. doi: 10.1097/01.CCM.0000206110.94385.C4.
    1. Kerbaul F, Collart F, Giorgi R, Oddoze C, Lejeune PJ, Guidon C, Caus T, Bellezza M, Gouin F. Increased plasma levels of pro-brain natriuretic peptide in patients with cardiovascular complications following off-pump coronary artery surgery. Intensive Care Med. 2004;30:1799–1806. doi: 10.1007/s00134-004-2299-0.
    1. Rau EE, Shine KI, Gervais A, Douglas AM, Amos EC., 3rd Enhanced mechanical recovery of anoxic and ischemic myocardium by amino acid perfusion. Am J Physiol. 1979;236:H873–H879.
    1. Pisarenko OI. Mechanisms of myocardial protection by amino acids: facts and hypotheses. Clin Exp Pharmacol Physiol. 1996;23:627–633. doi: 10.1111/j.1440-1681.1996.tb01748.x.
    1. Lazar HL, Buckberg GD, Manganaro AJ, Becker H, Maloney JV., Jr Reversal of ischemic damage with amino acid substrate enhancement during reperfusion. Surgery. 1980;88:702–709.
    1. Burns AH, Reddy WJ. Amino acid stimulation of oxygen and substrate utilization by cardiac myocytes. Am J Physiol. 1978;235:E461–E466.
    1. Pisarenko OI, Oleynikov OD, Shulzhenko VS, Studneva IM, Ryff IM, Kapelko VI. Association of myocardial glutamate and aspartate pool and functional recovery of postischemic heart. Biochem Med Metab Biol. 1989;42:105–117. doi: 10.1016/0885-4505(89)90046-7.
    1. Mudge GH, Jr, Mills RM, Jr, Taegtmeyer H, Gorlin R, Lesch M. Alterations of myocardial amino acid metabolism in chronic ischemic heart disease. J Clin Investig. 1976;58:1185–1192. doi: 10.1172/JCI108571.
    1. Thomassen AR, Nielsen TT, Bagger JP, Henningsen P. Myocardial exchanges of glutamate, alanine and citrate in controls and patients with coronary artery disease. Clin Sci. 1983;64:33–40. doi: 10.1042/cs0640033.
    1. Svedjeholm R, Ekroth R, Joachimsson PO, Ronquist G, Svensson S, Tyden H. Myocardial uptake of amino acids and other substrates in relation to myocardial oxygen consumption four hours after cardiac operations. J Thorac Cardiovasc Surg. 1991;101:688–694. doi: 10.1016/S0022-5223(19)36700-5.
    1. Svedjeholm R, Vanhanen I, Hakanson E, Joachimsson PO, Jorfeldt L, Nilsson L. Metabolic and hemodynamic effects of intravenous glutamate infusion early after coronary operations. J Thorac Cardiovasc Surg. 1996;112:1468–1477. doi: 10.1016/S0022-5223(96)70005-3.
    1. Pisarenko OI, Lepilin MG, Ivanov VE. Cardiac metabolism and performance during l-glutamic acid infusion in postoperative cardiac failure. Clin Sci. 1986;70:7–12. doi: 10.1042/cs0700007.
    1. Vidlund M, Hakanson E, Friberg O, Juhl-Andersen S, Holm J, Vanky F, Sunnermalm L, Borg JO, Sharma R, Svedjeholm R. GLUTAMICS–a randomized clinical trial on glutamate infusion in 861 patients undergoing surgery for acute coronary syndrome. J Thorac Cardiovasc Surg. 2012;144(922–30):e7.
    1. Vanhanen I, Svedjeholm R, Hakanson E, Joachimsson PO, Jorfeldt L, Nilsson L, Vanky F. Assessment of myocardial glutamate requirements early after coronary artery bypass surgery. Scand Cardiovasc J. 1998;32:145–152. doi: 10.1080/14017439850140102.
    1. Svedjeholm R, Hakanson E, Szabo Z. Routine SvO2 measurement after CABG surgery with a surgically introduced pulmonary artery catheter. Eur J Cardiothorac Surg. 1999;16:450–457. doi: 10.1016/S1010-7940(99)00287-0.
    1. Svedjeholm R, Vidlund M, Vanhanen I, Hakanson E. A metabolic protective strategy could improve long-term survival in patients with LV-dysfunction undergoing CABG. Scand Cardiovasc J. 2010;44:45–58. doi: 10.3109/14017430903531008.
    1. Holm J, Hakanson E, Vanky F, Svedjeholm R. Mixed venous oxygen saturation predicts short- and long-term outcome after coronary artery bypass grafting surgery: a retrospective cohort analysis. Br J Anaesth. 2011;107:344–350. doi: 10.1093/bja/aer166.
    1. Holm J, Hakanson RE, Vanky F, Svedjeholm R. Mixed venous oxygen saturation is a prognostic marker after surgery for aortic stenosis. Acta Anaesthesiol Scand. 2010;54:589–595. doi: 10.1111/j.1399-6576.2009.02205.x.
    1. Dahlin LG, Kagedal B, Nylander E, Olin C, Rutberg H, Svedjeholm R. Unspecific elevation of plasma troponin-T and CK-MB after coronary surgery. Scand Cardiovasc J. 2003;37:283–287. doi: 10.1080/14017430310014948.
    1. Doenst T, Amorim PA. Metabolic therapy in cardiac surgery—”optimizing the engine’s fuel supply and more…”. Scand Cardiovasc J. 2010;44:4–8. doi: 10.3109/14017430903469928.
    1. Vidlund M, Tajik B, Hakanson E, Friberg O, Holm J, Vanky F, Svedjeholm R. Post hoc analysis of the glutamics-trial: intravenous glutamate infusion and use of inotropic drugs after cabg. BMC Anesthesiol. 2016;16:54. doi: 10.1186/s12871-016-0216-z.
    1. Svedjeholm R, Hakanson E, Vanhanen I. Rationale for metabolic support with amino acids and glucose-insulin-potassium (GIK) in cardiac surgery. Ann Thorac Surg. 1995;59:S15–S22. doi: 10.1016/0003-4975(94)00917-V.
    1. Thomassen A, Nielsen TT, Bagger JP, Pedersen AK, Henningsen P. Antiischemic and metabolic effects of glutamate during pacing in patients with stable angina pectoris secondary to either coronary artery disease or syndrome X. Am J Cardiol. 1991;68:291–295. doi: 10.1016/0002-9149(91)90821-2.
    1. Slogoff S, Keats AS. Does perioperative myocardial ischemia lead to postoperative myocardial infarction? Anesthesiology. 1985;62:107–114. doi: 10.1097/00000542-198502000-00002.
    1. Langenberg CJ, Pietersen HG, Geskes G, Wagenmakers AJ, Lange SD, Schouten HJ, Soeters PB. The effect of glutamate infusion on cardiac performance is independent of changes in metabolism in patients undergoing routine coronary artery bypass surgery. Clin Sci. 2001;101:573–580. doi: 10.1042/cs1010573.
    1. Young YR, Sheu BF, Li WC, Hsieh TM, Hung CW, Chang SS, Lee CC. Predictive value of plasma brain natriuretic peptide for postoperative cardiac complications–a systemic review and meta-analysis. J Crit Care. 2014;29(696):e1–e10.
    1. Crescenzi G, Landoni G, Bignami E, Belloni I, Biselli C, Rosica C, Guarracino F, Marino G, Zangrillo A. N-terminal B-natriuretic peptide after coronary artery bypass graft surgery. J Cardiothorac Vasc Anesth. 2009;23:147–150. doi: 10.1053/j.jvca.2008.10.002.
    1. Vanky F, Hakanson E, Maros T, Svedjeholm R. Different characteristics of postoperative heart failure after surgery for aortic stenosis and coronary disease. Scand Cardiovasc J. 2004;38:152–158. doi: 10.1080/14017430410029734.
    1. Rao V, Ivanov J, Weisel RD, Ikonomidis JS, Christakis GT, David TE. Predictors of low cardiac output syndrome after coronary artery bypass. J Thorac Cardiovasc Surg. 1996;112:38–51. doi: 10.1016/S0022-5223(96)70176-9.
    1. Fellahi JL, Parienti JJ, Hanouz JL, Plaud B, Riou B, Ouattara A. Perioperative use of dobutamine in cardiac surgery and adverse cardiac outcome: propensity-adjusted analyses. Anesthesiology. 2008;108:979–987. doi: 10.1097/ALN.0b013e318173026f.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다